articleTop 1% cited

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

The Lancet Oncology · 2017 · Vol. 19(1) · pp. 40–50

Carsten Denkert✉(Charité - Universitätsmedizin Berlin)Gϋnter von Minckwitz(German Breast group)Silvia Darb‐Esfahani(Berlin Institute of Health at Charité - Universitätsmedizin Berlin)Bianca Lederer(German Breast group)Barbara Ingold Heppner(Freie Universität Berlin)Karsten E. Weber(German Breast group)Jan Budczies(German Cancer Society)Jens Huober(Universität Ulm)Frederick Klauschen(Humboldt-Universität zu Berlin)Jenny Furlanetto(German Breast group)Wolfgang Schmitt(Humboldt-Universität zu Berlin)Jens‐Uwe Blohmer(Charité - Universitätsmedizin Berlin)Thomas Karn(University Hospital Frankfurt)Berit M. Pfitzner(Berlin Institute of Health at Charité - Universitätsmedizin Berlin)Sherko Kümmel(Kliniken Essen-Mitte)Knut EngelsAndreas Schneeweiß(Heidelberg University)Arndt Hartmann(Friedrich-Alexander-Universität Erlangen-Nürnberg)Aurelia Noske(Technical University of Munich)Peter A. Fasching(Friedrich-Alexander-Universität Erlangen-Nürnberg)Christian Jackisch(Sana Klinikum Offenbach)Marion van Mackelenbergh(German Breast group)Hans‐Peter Sinn(Heidelberg University)Christian SchemClaus Hanusch(Rotkreuzklinikum München)Michael Untch(Helios Hospital Berlin-Buch)Sibylle Loibl(German Breast group)

View via DOI Publisher page

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Cancer Cells and MetastasisMedicineBreast cancerTumor-infiltrating lymphocytesOncologyInternal medicineChemotherapyCancerNeoadjuvant therapyTriple-negative breast cancerStage (stratigraphy)

MeSH terms

AdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansMiddle AgedRisk FactorsTime FactorsBiomarkers, TumorRandomized Controlled Trials as TopicLymphocytes, Tumor-InfiltratingTreatment OutcomeChemotherapy, AdjuvantDisease-Free SurvivalReceptor, ErbB-2